Elevated expression of EZH2 correlates with metastatic tumor growth and with clinically aggressive behaviors in prostate and breast cancer [67], have been recognized as a negative prognostic marker for a number of breast and prostate cancer patients [68], [69], and are associated with poor outcomes to tamoxifen therapy in advanced breast cancer patients [70]. This evidence concerns the gene EZH2 and prostate carcinoma.